Home
RXRX
RXRX News

Latest Recursion Pharmaceuticals Inc. (RXRX) News on March 31, 2025

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?

Motley Fool

a day ago

Should Investors Buy These 2 Beaten-Down Artificial Intelligence (AI) Healthcare Stocks?

Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?

Insider Monkey

5 days ago

Is Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) the Best AI Stock to Invest in According to Reddit?

Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?

Insider Monkey

6 days ago

Why Recursion Pharmaceuticals Inc. (RXRX) Performed Worst On Tuesday?

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

Zacks

11 days ago

Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Simply Wall St.

13 days ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Jumps 12% Following US$500M Equity Offering

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?

Insider Monkey

13 days ago

Why Recursion Pharmaceuticals (RXRX) Went Up on Monday?

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

GlobeNewswire

13 days ago

Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

Big tech meets biotech: Recursion and the AI gold rush in pharma

Pharmaceutical Technology

14 days ago

Big tech meets biotech: Recursion and the AI gold rush in pharma

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’

Insider Monkey

19 days ago

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘We’re Going To Have To Hold Off’

Why Recursion Pharmaceuticals Stock Is Sinking Today

Motley Fool

21 days ago

Why Recursion Pharmaceuticals Stock Is Sinking Today

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?

Motley Fool

23 days ago

Is This Beaten-Down Artificial Intelligence (AI) Stock a Buy?

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

Motley Fool

24 days ago

4 Things You Need to Know if You Buy Recursion Pharmaceuticals Stock Today

This Biotech Stock Could Be the Best Investment of the Decade

Motley Fool

25 days ago

This Biotech Stock Could Be the Best Investment of the Decade

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

Motley Fool

a month ago

Down Over 40%, Is Recursion Pharmaceuticals a Buy on the Dip?

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts

Simply Wall St.

a month ago

News Flash: Analysts Just Made A Sizeable Upgrade To Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Forecasts

Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday

Insider Monkey

a month ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Crashed on Monday

GuruFocus.com

a month ago

Recursion Pharmaceuticals Inc (RXRX) Q4 2024 Earnings Call Highlights: Strong Financial ...

Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering

Simply Wall St.

a month ago

Recursion Pharmaceuticals (NasdaqGS:RXRX) Surges 6% Following US$500 Million Follow-On Equity Offering

Company News for Mar 3, 2025

Zacks

a month ago

Company News for Mar 3, 2025

Recursion Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

Simply Wall St.

a month ago

Recursion Pharmaceuticals Full Year 2024 Earnings: Misses Expectations

MT Newswires

a month ago

Sector Update: Health Care Stocks Steady Pre-Bell Friday

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates

Zacks

a month ago

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates

MT Newswires

a month ago

Recursion Pharmaceuticals Q4 Loss Widens, Revenue Declines

Associated Press Finance

a month ago

Recursion Pharmaceuticals: Q4 Earnings Snapshot

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

GlobeNewswire

a month ago

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Pharma Voice

a month ago

AI deals are surging, and Recursion’s ongoing Exscientia merger points to a new world of integration

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

GlobeNewswire

a month ago

Recursion to Report Fourth Quarter and Fiscal Year 2024 Business Updates and Financial Results on February 28th

Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?

Insider Monkey

a month ago

Recursion Pharmaceuticals, Inc. (RXRX): The Best Performing Pharma Stock So Far in 2025?

Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)

Insider Monkey

a month ago

Cathie Wood Explains Why She Likes Recursion Pharmaceuticals, Inc. (RXRX)

Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025

Insider Monkey

a month ago

Why Recursion Pharmaceuticals, Inc. (RXRX) is the Best Performing Healthcare Stock So Far in 2025

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

GlobeNewswire

a month ago

Altitude Lab Launches Pre-seed Venture Fund, Anchored by Recursion CEO Chris Gibson, Enabling SBIR-awarded Biotechs Hit by Funding Gap to Build in Salt Lake City

Recursion CEO launches pre-seed fund in response to NIH cuts

BioPharma Dive

a month ago

Recursion CEO launches pre-seed fund in response to NIH cuts

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

Investor's Business Daily

a month ago

Recursion Pharmaceuticals Stock Scores RS Ratings Over 90

Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)

Insider Monkey

a month ago

Why Jensen Huang’s Company Is Betting On Recursion Pharmaceuticals, Inc. (RXRX)

Altitude Lab Startups Raise $154M in Capital

GlobeNewswire

a month ago

Altitude Lab Startups Raise $154M in Capital

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock

Zacks

a month ago

Recursion Pharmaceuticals Before Q4 Earnings: How to Play the Stock

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week

Insider Monkey

a month ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared Last Week

Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday?

Insider Monkey

a month ago

Why Recursion Pharmaceuticals Inc. (RXRX) Soared on Friday?

Why Recursion Pharmaceuticals Stock Is Soaring Today

Motley Fool

a month ago

Why Recursion Pharmaceuticals Stock Is Soaring Today

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Laps the Stock Market: Here's Why

Why Recursion Pharmaceuticals Inc. (RXRX) Surged On Wednesday

Insider Monkey

2 months ago

Why Recursion Pharmaceuticals Inc. (RXRX) Surged On Wednesday

Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday?

Insider Monkey

2 months ago

Why Recursion Pharmaceuticals (RXRX) Stock Went Down On Thursday?

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

GlobeNewswire

2 months ago

Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Ascends While Market Falls: Some Facts to Note

Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) recent US$130m drop adds to long-term losses

Simply Wall St.

2 months ago

Institutional owners may consider drastic measures as Recursion Pharmaceuticals, Inc.'s (NASDAQ:RXRX) recent US$130m drop adds to long-term losses

Is Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025?

Insider Monkey

2 months ago

Is Recursion Pharmaceuticals (RXRX) the Cheap AI Stock to Buy in 2025?

Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan’s ‘Neutral’ Outlook

Insider Monkey

2 months ago

Recursion Pharmaceuticals (RXRX): Industrializing Drug Discovery with AI Amid J.P. Morgan’s ‘Neutral’ Outlook

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Zacks

2 months ago

Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday

Insider Monkey

2 months ago

Why Recursion Pharmaceuticals, Inc. (RXRX) Soared on Wednesday

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Motley Fool

2 months ago

2 Growth Stocks That Could Rocket Higher in the First Quarter of 2025

Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth

Insider Monkey

2 months ago

Recursion Pharmaceuticals, Inc. (RXRX): Revolutionizing Drug Discovery with AI and Strategic Collaborations for Strong Growth

Is Recursion Pharmaceuticals Stock a Buy?

Motley Fool

2 months ago

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

Zacks

3 months ago

Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth Knowing

MT Newswires

3 months ago

Recursion Pharmaceuticals Insider Sold Shares Worth $287,200, According to a Recent SEC Filing

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

Zacks

3 months ago

Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?

MT Newswires

3 months ago

KeyBanc Lowers Price Target on Recursion Pharmaceuticals to $10 From $12, Keeps Overweight Rating

Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA

TipRanks

3 months ago

Recursion Pharmaceuticals price target lowered to $10 from $12 at BofA

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips

The Wall Street Journal

3 months ago

AMD Invests in Drug-Discovery Company Absci in Push to Sell AI Chips

MT Newswires

3 months ago

BofA Securities Cuts Price Target on Recursion Pharmaceuticals to $10 From $12, Maintains Neutral Rating

MT Newswires

3 months ago

Recursion Pharmaceuticals Gets Regulatory Approvals for 2 Drug Trials

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

GlobeNewswire

3 months ago

Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

GlobeNewswire

3 months ago

Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Is Recursion Pharmaceuticals Stock a Millionaire Maker?

Motley Fool

3 months ago

Is Recursion Pharmaceuticals Stock a Millionaire Maker?

1 Artificial Intelligence (AI) Stock That Could Soar in 2025

Motley Fool

3 months ago

1 Artificial Intelligence (AI) Stock That Could Soar in 2025

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

GlobeNewswire

3 months ago

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)

Insider Monkey

4 months ago

Jim Cramer Says He Was Wrong on NVIDIA Holding Recursion Pharmaceuticals (RXRX)

Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials

Insider Monkey

4 months ago

Recursion Pharmaceuticals’ (RXRX) AI-Driven Cancer Treatment Shows Promise in Early Trials

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

Insider Monkey

4 months ago

Why Recursion Pharmaceuticals (RXRX) Is the Worst ARK Stock to Buy According to Short Sellers

MT Newswires

4 months ago

Recursion Pharmaceuticals Says Potential Advanced Solid Tumor Treatment Well Tolerated

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

GlobeNewswire

4 months ago

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

MT Newswires

4 months ago

Recursion Pharmaceuticals Insider Sold Shares Worth $285,600, According to a Recent SEC Filing

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘It Is Worthwhile Speculation’

Insider Monkey

4 months ago

Jim Cramer on Recursion Pharmaceuticals, Inc. (RXRX): ‘It Is Worthwhile Speculation’

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

GlobeNewswire

4 months ago

Recursion announces first patient dosed in Phase 1/2 clinical study of REC-1245, a potential first-in-class, RBM39 degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One

Benzinga

4 months ago

Jim Cramer: Reddit Is 'Fabulous,' Dow Is A 'Tough' One

2 Innovative Stocks That Could Deliver Outsize Returns

Motley Fool

4 months ago

2 Innovative Stocks That Could Deliver Outsize Returns

MT Newswires

4 months ago

Recursion Pharmaceuticals, Exscientia Complete Business Combination

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

GlobeNewswire

4 months ago

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes

Investor's Business Daily

5 months ago

Nvidia Discloses Stake In Applied Digital, Keeps Arm, SoundHound Stakes

MT Newswires

5 months ago

Recursion Pharmaceuticals, Exscientia Shareholders Approve Proposed Combination

Recursion and Exscientia Shareholders Approve the Proposed Combination

GlobeNewswire

5 months ago

Recursion and Exscientia Shareholders Approve the Proposed Combination

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

GlobeNewswire

5 months ago

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud’s Model Garden

Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher

Simply Wall St.

5 months ago

Analysts' Revenue Estimates For Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Are Surging Higher

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

Associated Press Finance

5 months ago

Recursion Pharmaceuticals: Q3 Earnings Snapshot

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

GlobeNewswire

5 months ago

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect

GuruFocus.com

5 months ago

Recursion Pharmaceuticals Inc (RXRX) Q3 2024 Earnings Report Preview: What To Expect

Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

Motley Fool

5 months ago

Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

GlobeNewswire

5 months ago

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

Motley Fool

5 months ago

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know

Zacks

5 months ago

Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know

Recursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech Innovation

Insider Monkey

5 months ago

Recursion Pharmaceuticals (RXRX): A Promising Small-Cap in Biotech Innovation

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

GlobeNewswire

5 months ago

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

State Street Corp's Strategic Acquisition in the Biotechnology Sector

GuruFocus.com

5 months ago

State Street Corp's Strategic Acquisition in the Biotechnology Sector

Prediction: These 2 Stocks Could Soar in 2025

Motley Fool

5 months ago

Prediction: These 2 Stocks Could Soar in 2025

Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know

Zacks

6 months ago

Recursion Pharmaceuticals (RXRX) Stock Moves -0.74%: What You Should Know

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Motley Fool

6 months ago

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

Share on Social Networks: